

0570
0530

8



OIPE

RAW SEQUENCE LISTING

DATE: 06/04/2002

PATENT APPLICATION: US/09/894,550

TIME: 13:25:51

Input Set : A:\083AUSSEQ LST.txt

Output Set: N:\CRF3\06042002\I894550.raw

ENTERED

3 <110> APPLICANT: Abbott Laboratories
 4 Collinson, Albert
 5 Ghayur, Tariq
 6 Avgerinos, George
 7 Dixon, Richard
 8 Kaymakcalan, Zehra
 10 <120> TITLE OF INVENTION: DUAL SPECIFICITY ANTIBODIES AND METHODS OF MAKING AND USING
 12 <130> FILE REFERENCE: BBC-083A US
 14 <140> CURRENT APPLICATION NUMBER: US 09/894,550
 15 <141> CURRENT FILING DATE: 2001-06-28
 17 <150> PRIOR APPLICATION NUMBER: US 60/215,379
 18 <151> PRIOR FILING DATE: 2000-06-29
 20 <160> NUMBER OF SEQ ID NOS: 4
 22 <170> SOFTWARE: PatentIn version 3.1
 24 <210> SEQ ID NO: 1
 25 <211> LENGTH: 9
 26 <212> TYPE: PRT
 27 <213> ORGANISM: Artificial Sequence
 29 <220> FEATURE:
 30 <223> OTHER INFORMATION: dual specificity antigen
 32 <400> SEQUENCE: 1
 34 Asn Glu Ala Gln Asn Ile Thr Asp Phe
 35 1 5
 38 <210> SEQ ID NO: 2
 39 <211> LENGTH: 18
 40 <212> TYPE: PRT
 41 <213> ORGANISM: Artificial Sequence
 43 <220> FEATURE:
 44 <223> OTHER INFORMATION: consensus sequence
 46 <220> FEATURE:
 47 <221> NAME/KEY: misc_feature
 48 <222> LOCATION: (18)..(18)
 49 <223> OTHER INFORMATION: Xaa is Pro or Gly
 52 <400> SEQUENCE: 2
 54 Met Ala Phe Leu Arg Ala Asn Gln Asn Asn Gly Lys Ile Ser Val Ala
 55 1 5 10 15
 58 Leu Xaa
 62 <210> SEQ ID NO: 3
 63 <211> LENGTH: 16
 64 <212> TYPE: PRT
 65 <213> ORGANISM: Artificial Sequence
 67 <220> FEATURE:
 68 <223> OTHER INFORMATION: hybrid peptide

RAW SEQUENCE LISTING

DATE: 06/04/2002

PATENT APPLICATION: US/09/894,550

TIME: 13:25:51

Input Set : A:\083AUSSEQ LST.txt

Output Set: N:\CRF3\06042002\I894550.raw

```

70 <400> SEQUENCE: 3
72 Thr Lys Gly Gly Gln Asp Ile Thr Asp Phe Gln Ile Leu Glu Asn Gln
73 1          5          10          15
76 <210> SEQ ID NO: 4
77 <211> LENGTH: 153
78 <212> TYPE: PRT
79 <213> ORGANISM: Artificial Sequence
81 <220> FEATURE:
82 <223> OTHER INFORMATION: hybrid peptide
84 <400> SEQUENCE: 4
86 Ala Pro Val Arg Ser Leu Asn Cys Thr Leu Arg Asp Ser Gln Gln Lys
87 1          5          10          15
90 Ser Leu Val Met Ser Gly Pro Tyr Glu Leu Lys Ala Leu His Leu Gln
91          20          25          30
94 Gly Gln Asp Met Glu Gln Gln Val Val Phe Ser Met Gly Ala Tyr Lys
95          35          40          45
98 Ser Ser Lys Asp Asp Ala Lys Ile Thr Val Ile Leu Gly Leu Lys Glu
99          50          55          60
102 Lys Asn Leu Tyr Leu Ser Cys Val Leu Lys Asp Asp Lys Pro Thr Leu
103 65          70          75          80
106 Gln Leu Glu Ser Val Asp Pro Lys Asn Tyr Pro Lys Lys Lys Met Glu
107          85          90          95
110 Lys Arg Phe Val Phe Asn Lys Ile Glu Ile Asn Asn Lys Leu Glu Phe
111          100          105          110
114 Glu Ser Ala Gln Phe Pro Asn Trp Tyr Ile Ser Thr Ser Gln Ala Glu
115          115          120          125
118 Asn Met Pro Val Phe Leu Gly Gly Thr Lys Gly Gly Gln Asp Ile Thr
119          130          135          140
122 Asp Phe Thr Met Gln Phe Val Ser Ser
123 145          150

```

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/09/894,550

DATE: 06/04/2002
TIME: 13:25:52

Input Set : A:\083AUSSEQ LST.txt
Output Set: N:\CRF3\06042002\I894550.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:2; Xaa Pos. 18